AFT Pharmaceuticals Limited Overview
Get informed when a big investor buys or sells
+ Follow24.20%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AFP.AX is 24.2%. That is above the sector sector average of 11.85%. Investors often review this figure alongside AFT Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AFP.AX currently prints 24.2% for ROE, while the sector average sits near 11.85%. That is roughly 104.2% above the sector mean. Large gaps often invite a closer look at AFT Pharmaceuticals Limited's growth, margins, and balance sheet.
Return on Equity shows how effectively AFT Pharmaceuticals Limited converts resources into returns. At 24.2%, AFP.AX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AFP.AX's ROE (24.2%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
